{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:58:33Z","timestamp":1760403513174,"version":"build-2065373602"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["JP21nf0101625"],"award-info":[{"award-number":["JP21nf0101625"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>DS-5670d is a monovalent lipid nanoparticle-messenger ribonucleic acid vaccine against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), containing an omicron XBB.1.5-derived antigen. This phase 3 non-inferiority study assessed the immunogenicity and safety of a single dose of DS-5670d according to participant immune status.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>Participants aged \u226512 years were stratified according to their history of both prior SARS-CoV-2 infection plus prior coronavirus disease 2019 vaccination (subpopulation A), prior infection only (subpopulation B), prior vaccination only (subpopulation C), or no history of either infection or vaccination (subpopulation D), and randomly assigned (1:1) to receive DS-5670d or monovalent BNT162b2 omicron XBB.1.5. The primary efficacy endpoint was geometric mean titer (GMT) of blood neutralizing activity against SARS-CoV-2 (omicron XBB.1.5) and seroresponse rate at day 29 after study vaccine administration in the combined ABC subpopulations (DS-5670d, <jats:italic><jats:italic>n<\/jats:italic><\/jats:italic>\u2009=\u2009362 versus BNT162b2, <jats:italic><jats:italic>n<\/jats:italic><\/jats:italic>\u2009=\u2009363). Prespecified non-inferiority margins required that the lower limit of the 95% confidence interval (CI) exceeded 0.67 for the GMT ratio and \u201310% for the difference in seroresponse. The adjusted GMT ratio was 1.218 (95% confidence interval [CI], 1.059, 1.401). Seroresponse rates were 87.3% (DS-5670d) and 82.9% (BNT162b2); adjusted difference 4.5% (95% CI, \u20130.70, 9.71). Both results exceeded the non-inferiority margins and the study met the primary endpoint. Immunogenicity data in the overall ABCD population also met non-inferiority criteria. There were no apparent immunogenicity differences according to age or sex, and analyses suggested that even unvaccinated persons achieved an adequate immune response following a single dose of DS-5670d. There were no major differences in the incidence or severity of adverse events between the study vaccination groups. The main study limitation was the short duration of follow-up.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>A single dose of DS-5670d was immunogenically non-inferior to BNT162b2 and acceptably safe in persons with or without a history of prior infection and\/or vaccination.<\/jats:p>\n<jats:p><jats:bold>Trial registration<\/jats:bold><\/jats:p>\n<jats:p>Japan Registry of Clinical Trials (jRCT2031230424)<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004499","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:24:27Z","timestamp":1760376267000},"page":"e1004499","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study"],"prefix":"10.1371","volume":"22","author":[{"given":"Ami","family":"Kawamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyasu","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Furihata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aisaku","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7124-8877","authenticated-orcid":true,"given":"Fumihiko","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"1","key":"pmed.1004499.ref001","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/14760584.2024.2346589","article-title":"Changing epidemiology of COVID-19: potential future impact on vaccines and vaccination strategies","volume":"23","author":"T Ulrichs","year":"2024","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"pmed.1004499.ref002","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41541-024-00867-3","article-title":"Progress with COVID vaccine development and implementation","volume":"9","author":"RW Titball","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"1","key":"pmed.1004499.ref003","article-title":"COVID-19 vaccines\u2019 protection over time and the need for booster doses; a systematic review","volume":"10","author":"O Dadras","year":"2022","journal-title":"Arch Acad Emerg Med"},{"issue":"6","key":"pmed.1004499.ref004","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/08971900211009650","article-title":"Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273","volume":"35","author":"SP Teo","year":"2022","journal-title":"J Pharm Pract"},{"issue":"10","key":"pmed.1004499.ref005","article-title":"A Hitchhiker\u2019s guide to worldwide COVID-19 vaccinations: a detailed review of monovalent and bivalent vaccine schedules, COVID-19 vaccine side effects, and effectiveness against omicron and delta variants","volume":"14","author":"L Goyal","year":"2022","journal-title":"Cureus"},{"issue":"48","key":"pmed.1004499.ref006","doi-asserted-by":"crossref","first-page":"2300173","DOI":"10.2807\/1560-7917.ES.2023.28.48.2300173","article-title":"Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case-control study, United Kingdom, 2022","volume":"28","author":"A Chatzilena","year":"2023","journal-title":"Euro Surveill"},{"issue":"13","key":"pmed.1004499.ref007","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jama.2021.2828","article-title":"The potential future of the COVID-19 pandemic: will SARS-CoV-2 become a recurrent seasonal infection?","volume":"325","author":"CJL Murray","year":"2021","journal-title":"JAMA"},{"key":"pmed.1004499.ref008","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes changes to simplify use of bivalent mRNA COVID-19 vaccines; 18 April 2023 [cited 30 Jan 2025). Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines"},{"key":"pmed.1004499.ref009","unstructured":"European Centre for Disease Prevention and Control, European Medicines Agency. ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants; 6 June 2023 [accessed 30 Jan 2025]. Available from: https:\/\/www.ema.europa.eu\/system\/files\/documents\/other\/ecdc-ema_statement_on_updating_covid-19_vaccines_composition_for_new_sars-cov-2_virus_variants_en.pdf"},{"issue":"42","key":"pmed.1004499.ref010","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.15585\/mmwr.mm7242e1","article-title":"Use of updated COVID-19 vaccines 2023-2024 formula for persons aged \u22656 months: recommendations of the Advisory Committee on Immunization Practices\u2016United States, September 2023","volume":"72","author":"JJ Regan","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pmed.1004499.ref011","unstructured":"European Medicines Agency. News: ETF recommends updating COVID-19 vaccines to target new JN.1 variant; 30 April 2024 [cited 30 Jan 2025]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/etf-recommends-updating-covid-19-vaccines-target-new-jn1-variant"},{"key":"#cr-split#-pmed.1004499.ref012.1","unstructured":"US Food and Drug Administration. Updated COVID-19 vaccines for use in the United States beginning in Fall 2024"},{"key":"#cr-split#-pmed.1004499.ref012.2","unstructured":"5 June 2024 [cited 30 Jan 2025]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/updated-covid-19-vaccines-use-united-states-beginning-fall-2024"},{"issue":"3","key":"pmed.1004499.ref013","first-page":"118","article-title":"Development of an mRNA vaccine against COVID-19","volume":"3","author":"M Yabuta","year":"2021","journal-title":"Transl Regul Sci"},{"issue":"38","key":"pmed.1004499.ref014","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1016\/j.vaccine.2023.07.012","article-title":"DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: results from a phase 2 clinical study","volume":"41","author":"K Toyama","year":"2023","journal-title":"Vaccine"},{"key":"pmed.1004499.ref015","doi-asserted-by":"crossref","first-page":"1445459","DOI":"10.3389\/fimmu.2024.1445459","article-title":"Booster vaccination using bivalent DS-5670a\/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5-11 years: a phase 2\/3, randomized, active-controlled study","volume":"15","author":"R Suzuki","year":"2024","journal-title":"Front Immunol"},{"key":"pmed.1004499.ref016","unstructured":"Daiichi-Sankyo. Press release: Daichirona for intramuscular injection for booster vaccination approved in Japan as omicron XBB.1.5-adapted monovalent mRNA vaccine against COVID-19; 28 Nov 2023 [cited 30 Jan 2025]. Available from: https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202311\/20231128_E.pdf"},{"key":"pmed.1004499.ref017","doi-asserted-by":"crossref","first-page":"1113156","DOI":"10.3389\/fimmu.2023.1113156","article-title":"A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults","volume":"14","author":"K Xu","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"pmed.1004499.ref018","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2188\/jea.JE20230106","article-title":"Effectiveness of BNT162b2 against infection, symptomatic infection, and hospitalization among older adults aged \u226565 years during the delta variant predominance in Japan: the VENUS Study","volume":"34","author":"W Mimura","year":"2024","journal-title":"J Epidemiol"},{"issue":"2","key":"pmed.1004499.ref019","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2116771","article-title":"Adolescents, parents, and Covid-19 vaccination\u2014who should decide?","volume":"386","author":"S McGrew","year":"2022","journal-title":"N Engl J Med"},{"key":"pmed.1004499.ref020","unstructured":"Japan Ministry of Internal Affairs and Communications. Statistics Topic No. 138: Japan\u2019s elderly seen from statistics (Respect for the Aged Day); 18 Sep 2023 [cited 30 Jan 2025]. Available from: https:\/\/www.stat.go.jp\/data\/topics\/pdf\/topi138_01.pdf"},{"issue":"1","key":"pmed.1004499.ref021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1108\/PAP-10-2022-0123","article-title":"Lessons from the COVID-19 pandemic: strategies and challenges for an aging society in Japan","volume":"26","author":"T Hasegawa","year":"2023","journal-title":"PAP"},{"key":"pmed.1004499.ref022","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and gender differences in the outcomes of vaccination over the life course","volume":"33","author":"KL Flanagan","year":"2017","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"4","key":"pmed.1004499.ref023","article-title":"Gender differences in vaccine therapy: where are we in COVID-19 pandemic?","volume":"91","author":"T Ciarambino","year":"2021","journal-title":"Monaldi Arch Chest Dis"},{"key":"pmed.1004499.ref024","doi-asserted-by":"crossref","first-page":"108906","DOI":"10.1016\/j.intimp.2022.108906","article-title":"Adverse events following COVID-19 vaccination: a systematic review and meta-analysis","volume":"109","author":"H Kouhpayeh","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"pmed.1004499.ref025","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3390\/vaccines10040488","article-title":"The side effects and adverse clinical cases reported after COVID-19 immunization","volume":"10","author":"R Rabail","year":"2022","journal-title":"Vaccines (Basel)"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:24:34Z","timestamp":1760376274000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004499"}},"subtitle":[],"editor":[{"given":"Amitabh Bipin","family":"Suthar","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004499","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]}}}